The estimated Net Worth of Harish Manwani is at least $1.03 Million dollars as of 3 May 2022. Mr. Manwani owns over 2,223 units of Gilead Sciences stock worth over $637,564 and over the last 13 years he sold GILD stock worth over $0. In addition, he makes $394,977 as Independent Director at Gilead Sciences.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Manwani GILD stock SEC Form 4 insiders trading
Harish has made over 9 trades of the Gilead Sciences stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 2,223 units of GILD stock worth $179,930 on 3 May 2022.
The largest trade he's ever made was exercising 5,099 units of Gilead Sciences stock on 8 March 2019 worth over $412,713. On average, Harish trades about 377 units every 26 days since 2011. As of 3 May 2022 he still owns at least 7,877 units of Gilead Sciences stock.
You can see the complete history of Mr. Manwani stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Harish Manwani biography
Harish M. Manwani serves as Independent Director of the Company. Mr. Manwani is a Senior Operating Partner at The Blackstone Group L.P., a leading global alternative asset manager, which he joined in 2015. He previously was Chief Operating Officer of the Unilever Group from 2011 until his retirement in 2014. Mr. Manwani joined Unilever in 1976 as a management trainee in India and held senior management roles around the world, including North America, Latin America, Asia, Africa and Central and Eastern Europe. Mr. Manwani is an honors graduate from Bombay University. He holds a master’s degree in Management Studies, and he attended the Advanced Management Program at Harvard Business School. Mr. Manwani is the Chairman of Board of the Indian School of Business, and also serves on the board or directors of Whirlpool Corporation, Qualcomm Incorporated, Nielsen Holdings plc., EDBI Pte Ltd. and Tata Sons Private Limited. He previously served as the non-executive Chairman of Hindustan Unilever Limited from 2005 to 2018, and as a member of the board of directors of The Economic Development Board of Singapore from 2013 to 2019 and Pearson plc from 2013 to 2018.
What is the salary of Harish Manwani?
As the Independent Director of Gilead Sciences, the total compensation of Harish Manwani at Gilead Sciences is $394,977. There are 14 executives at Gilead Sciences getting paid more, with Daniel O'Day having the highest compensation of $29,107,900.
How old is Harish Manwani?
Harish Manwani is 66, he's been the Independent Director of Gilead Sciences since 2018. There are 5 older and 20 younger executives at Gilead Sciences. The oldest executive at Gilead Sciences, Inc. is Richard Whitley, 74, who is the Independent Director.
What's Harish Manwani's mailing address?
Harish's mailing address filed with the SEC is 333 LAKESIDE DRIVE, , FOSTER CITY, CA, 94404.
Insiders trading at Gilead Sciences
Over the last 22 years, insiders at Gilead Sciences have traded over $221,090,692 worth of Gilead Sciences stock and bought 30,121 units worth $1,879,767 . The most active insiders traders include John C Martin, Norbert W Bischofberger, and John F Milligan. On average, Gilead Sciences executives and independent directors trade stock every 9 days with the average trade being worth of $3,341,365. The most recent stock trade was executed by Deborah H Telman on 10 September 2024, trading 639 units of GILD stock currently worth $51,721.
What does Gilead Sciences do?
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
What does Gilead Sciences's logo look like?
Complete history of Mr. Manwani stock trades at Gilead Sciences, Qualcomm, Nielsen plc, and Whirlpool
Gilead Sciences executives and stock owners
Gilead Sciences executives and other stock owners filed with the SEC include:
-
Daniel O'Day,
Chairman of the Board, Chief Executive Officer -
Johanna Mercier,
Chief Commercial Officer -
Daniel P. O'Day,
Chairman & CEO -
Andrew Dickinson,
Chief Financial Officer, Executive Vice President -
Brett Pletcher,
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary -
Johanna Mercier,
Chief Commercial Officer -
Dr. Merdad V. Parsey M.D., Ph.D.,
Chief Medical Officer -
Merdad Parsey,
Chief Medical Officer -
Brett A. Pletcher,
Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. -
Andrew D. Dickinson,
Exec. VP & CFO -
Per Wold-Olsen,
Independent Director -
Richard Whitley,
Independent Director -
Kelly Kramer,
Independent Director -
Kevin Lofton,
Lead Independent Director -
Harish Manwani,
Independent Director -
Jacqueline Barton,
Independent Director -
Sandra Horning,
Independent Director -
Anthony Welters,
Director -
Javier Rodriguez,
Director -
Michael Quigley,
Senior Vice President - Research Biology -
Linda Higgins,
Senior Vice President - Head of External Innovation -
Jyoti Mehra,
Executive Vice President of Human Resources -
Dr. Linda Slanec Higgins Ph.D.,
Sr. VP & Head of External Innovation -
Jyoti K. Mehra,
Exec. VP of HR -
Deborah H. Telman,
Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. -
Dr. Diana M. Brainard M.D.,
Sr. VP of HIV & Emerging Viral Infections -
Dr. Taiyin Yang,
Exec. VP of Pharmaceutical Devel. & Manufacturing -
Jacquie Ross C.F.A.,
VP of Investor Relations -
Diane E. Wilfong,
Sr. VP, Corp. Controller & Chief Accounting Officer -
John Francis Cogan,
Director -
John W Madigan,
Director -
Robin L Washington,
SVP, CFO -
Norbert W Bischofberger,
SVP, Research -
James R Meyers,
SVP Comm Ops North America -
Nicholas G Moore,
Director -
Gayle E Wilson,
Director -
Kevin Young,
EVP, Commercial Operations -
Laura Hamill,
EVP, Worldwide Commercial Ops -
Carla A Hills,
Director -
Etienne Davignon,
Director -
Paul Rutherford Carter,
EVP Commercial Ops -
John C Martin,
President and CEO -
John F Milligan,
EVP, Chief Financial Officer -
John G Mc Hutchison,
Chief Scientific Off/HeadR&D -
James M Denny,
Director -
Gordon Earle Moore,
Director -
Kristen Metza,
SVP, Human Resources -
Gregg H Alton,
SVP, General Counsel -
Paul Berg,
Director -
Louis G Lange,
EVP Cardiovascular Therapeutic -
Taiyin Yang,
SVP, Pharm Dev & Mfg -
William A Lee,
SVP Research and PPD -
Anthony Caracciolo,
SVP -
Caroline Dorsa,
SVP, Chief Financial Officer -
John J Toole,
SVP -
George P Shultz,
Director -
Alan Bruce Montgomery,
SVP, Respiratory Therapeutics -
Michael K Inouye,
SVP -
Mark L Perry,
EVP Operations -
Cordell W Hull,
Director -
Diane E. Wilfong,
SVP, Controller & CAO -
Sandra Patterson,
SVP, Controllership -
Jeffrey Bluestone,
Director -
Deborah H Telman,
EVP, Corporate Affairs & GC -
Ted W Love,
Director